central nervous system lymphoma (Cancer)
Information
- Disease name
- central nervous system lymphoma
- Disease ID
- DOID:3234
- Description
- "A hematologic cancer that has_material_basis_in lymphoma located_in central nervous system." [url:https\://www.lls.org/lymphoma/non-hodgkin-lymphoma/treatment/treatment-for-aggressive-nhl-subtypes/central-nervous-system-cns-lymphoma]
Disease area statistics
[No Data.]
Chromosome band
[No Data.]
Annotation
| Genes | Mutation | Description | Source | Links |
|---|
| NCT ID | Status | Phase | Summary | Start date | Completion date |
|---|---|---|---|---|---|
| NCT03964090 | Active, not recruiting | Phase 2 | Temozolomide, Etoposide, Doxil, Dexamethasone, Ibrutinib, and Rituximab (TEDDI-R) in Aggressive B-cell Lymphomas With Secondary Involvement of the Central Nervous System (CNS) | June 27, 2019 | July 1, 2026 |
| NCT03962127 | Active, not recruiting | MIDNOR-STROKE- a Long Term Follow-up Study of Patients With First Ever Ischemic Stroke in Central Norway | May 1, 2015 | August 2026 | |
| NCT00221325 | Completed | Phase 1 | A Safety Study of Rituximab Plus MTX Injected Into the Cerebrospinal Fluid in the Treatment of Brain Lymphoma | April 2007 | March 2013 |
| NCT00581737 | Completed | Cognitive Functioning and Quality of Life in CNS Lymphoma | July 2000 | August 2009 | |
| NCT00916630 | Completed | Phase 1 | Treatment of Recurrent Primary or Secondary Central Nervous System (CNS) Lymphoma With ALIMTA (Pemetrexed) | January 2009 | September 2015 |
| NCT00967200 | Completed | Study of Tissue Samples From Patients With Glioma or Other Brain Tumors | November 2003 | November 2015 | |
| NCT01011920 | Completed | Phase 2 | Trial for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | November 2009 | March 2017 |
| NCT01458730 | Completed | Phase 2 | Nordic Study in Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma | May 2007 | August 2022 |
| NCT01722305 | Completed | Phase 1 | Pomalidomide and Dexamethasone in Treating Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma or Newly Diagnosed or Relapsed or Refractory Intraocular Lymphoma | April 8, 2013 | July 15, 2019 |
| NCT00103038 | Completed | N/A | Ferumoxytol in Improving MR Imaging in Patients With High-Grade Brain Tumors or Cerebral Metastases | June 4, 2004 | June 10, 2016 |
| NCT00153530 | Completed | Phase 4 | Whole Brain Irradiation in Primary Central Nervous System (CNS) Lymphoma (PCNSL) | May 2000 | May 2009 |
| NCT02652715 | Completed | N/A | Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma | January 19, 2016 | November 12, 2019 |
| NCT03342586 | Completed | Using a Novel Functional MRI Technique to Evaluate for Neurotoxicity | November 7, 2017 | August 4, 2022 | |
| NCT03690895 | Completed | Long-term Outcome of AIDS-related Primary Central Nervous System Lymphoma Treated With High Dose Methotrexate and Combined Antiretroviral Therapy | March 15, 2015 | October 1, 2016 | |
| NCT06213636 | Not yet recruiting | Phase 1/Phase 2 | Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL). | November 10, 2024 | December 10, 2025 |
| NCT03375619 | Recruiting | Long-term Follow-up Study of Patients Receiving CAR-T Cells | December 1, 2017 | January 1, 2035 | |
| NCT03684980 | Recruiting | Early Phase 1 | LTA Pilot Study of Glucarpidase in Patients With Central Nervous System Lymphoma | November 14, 2018 | November 2025 |
| NCT02952508 | Recruiting | Phase 2 | Study of Iopofosine I 131 (CLR 131) in Select B-Cell Malignancies (CLOVER-1) and Pivotal Expansion in Waldenstrom Macroglobulinemia | July 26, 2017 | June 30, 2025 |
| NCT05625594 | Recruiting | Phase 1 | Intracerebroventricular Administration of CD19-CAR T Cells (CD19CAR-CD28-CD3zeta-EGFRt-expressing Tcm-enriched T-lymphocytes) for the Treatment of Primary Central Nervous System Lymphoma | June 29, 2023 | July 29, 2027 |
| NCT05651178 | Recruiting | Early Phase 1 | Human CD19-CD22 Targeted T Cells Injection for Refractory/Relapsed Central Nervous System Leukemia/Lymphoma Patients | August 12, 2022 | August 31, 2025 |
| NCT05698147 | Recruiting | Phase 1/Phase 2 | Selinexor in Combination With MTX+Ritu to Treat R/R CNSL | August 3, 2023 | December 31, 2026 |
| NCT05816746 | Recruiting | Phase 2 | Decitabine and Anti-PD-1 in R/R DLBCL | May 15, 2023 | March 1, 2026 |
| NCT06031194 | Recruiting | Pharmacogenomics Effects on High-Dose Methotrexate Clearance in Patients With Diffuse Large B-Cell Lymphoma | May 10, 2023 | December 31, 2024 | |
| NCT04186520 | Recruiting | Phase 1/Phase 2 | CAR-20/19-T Cells in Patients With Relapsed Refractory B Cell Malignancies | May 18, 2020 | January 2025 |
| NCT04548648 | Recruiting | Phase 2 | A Pilot Study of Acalabrutinib in Relapsed/Refractory Primary and Secondary CNS Lymphomas | October 15, 2020 | February 22, 2033 |
| NCT04792489 | Recruiting | Phase 2 | DALY II USA/ MB-CART2019.1 for DLBCL | May 25, 2021 | December 31, 2026 |
| NCT04906902 | Recruiting | Phase 1/Phase 2 | Acalabrutinib in CNSL | August 23, 2021 | January 31, 2026 |
| NCT04938297 | Recruiting | Phase 2 | Rituximab,Zanubrutinib in Combination With Lenalidomide, Followed by Zanubrutinib or Lenalidomide Maintenance in Patients With Primary or Secondary CNS Lymphoma | May 26, 2021 | December 31, 2025 |
| NCT05011045 | Recruiting | Neurocognitive Outcomes After Whole Brain Radiation Therapy for Hematologic Malignancies | January 9, 2020 | October 31, 2026 | |
| NCT05054426 | Recruiting | Phase 3 | Intermediate Dose of IV MTX as CNS Prophylaxis for High Risk DLBCL | October 8, 2021 | October 8, 2025 |
| NCT05114330 | Recruiting | Secondary Central Nervous System Lymphoma Registry - Charité | June 8, 2011 | June 8, 2026 | |
| NCT05209620 | Recruiting | Phase 2 | Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma | December 21, 2021 | December 21, 2026 |
| NCT05260619 | Recruiting | Phase 2 | Lenalidomide Maintenance Treatment in Patients With Primary Central Nervous System Lymphoma | April 1, 2022 | April 1, 2028 |
| NCT02420795 | Terminated | Phase 1/Phase 2 | Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma | November 3, 2015 | November 16, 2020 |
| NCT03859544 | Unknown status | Molecular Prognosis of Lymphomas of the Central Nervous System (ALYCE-molecular) | January 1, 2016 | January 1, 2020 | |
| NCT00293475 | Unknown status | Phase 1/Phase 2 | Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma | October 14, 2005 | January 31, 2023 |
| NCT02623010 | Unknown status | Phase 2 | Bruton's Tyrosine Kinase Inhibitor Ibrutinib as Maintenance Treatment in Elderly Patients With Primary CNS Lymphoma | October 2016 | December 2023 |
| NCT04516655 | Unknown status | Phase 2 | A Phase II Trail of Chidamide ,Rituximab and Methotrexate in Lymphoma Patients | September 1, 2020 | August 30, 2023 |
- Disase is a (Disease Ontology)
- DOID:3620
- Cross Reference ID (Disease Ontology)
- ICD9CM:200.5
- Cross Reference ID (Disease Ontology)
- NCI:C9301
- Cross Reference ID (Disease Ontology)
- SNOMEDCT_US_2023_03_01:69110006
- Cross Reference ID (Disease Ontology)
- UMLS_CUI:C0280803
- Exact Synonym (Disease Ontology)
- Microglioma
- Exact Synonym (Disease Ontology)
- primary CNS lymphoma